MARKET

IONS

IONS

Ionis Pharmaceuticals
NASDAQ
77.63
+0.55
+0.71%
Pre Market: 77.63 0 0.00% 05:55 12/19 EST
OPEN
77.39
PREV CLOSE
77.08
HIGH
78.16
LOW
76.70
VOLUME
45
TURNOVER
25.10M
52 WEEK HIGH
83.61
52 WEEK LOW
23.95
MARKET CAP
12.57B
P/E (TTM)
-45.2970
1D
5D
1M
3M
1Y
5Y
1D
Ionis Pharmaceuticals (IONS): Revisiting Valuation After a Powerful Year-to-Date Share Price Rally
Simply Wall St · 6h ago
Ionis Pharmaceuticals Is Maintained at Outperform by RBC Capital
Dow Jones · 1d ago
RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $95
Benzinga · 1d ago
Ionis Pharmaceuticals price target raised to $95 from $82 at RBC Capital
TipRanks · 1d ago
Arrowhead price target raised to $100 from $70 at Piper Sandler
TipRanks · 1d ago
RBC Capital Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)
TipRanks · 1d ago
Is It Too Late to Consider Ionis After Its 126% Surge in 2025?
Simply Wall St · 2d ago
Ionis Pharmaceuticals Price Target Raised to $100.00/Share From $85.00 by Leerink Partners
Dow Jones · 3d ago
More
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Webull offers Ionis Pharmaceuticals Inc stock information, including NASDAQ: IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.